User profiles for "author:Mohamed El Kassas"

Mohamed El-Kassas

Endemic Medicine Department, Faculty of Medicine, Helwan University
Verified email at hq.helwan.edu.eg
Cited by 8282

[HTML][HTML] A multisociety Delphi consensus statement on new fatty liver disease nomenclature

ME Rinella, JV Lazarus, V Ratziu, SM Francque… - Hepatology, 2023 - journals.lww.com
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary
confounder terms and the use of potentially stigmatising language. This study set out to …

Hepatitis C infection in Egypt: prevalence, impact and management strategies

A Gomaa, N Allam, A Elsharkway… - Hepatic medicine …, 2017 - Taylor & Francis
Hepatitis C virus (HCV) infection is a major public health burden in Egypt, where it bears the
highest prevalence rate in the world. Estimates for prevalence are based upon data reported …

National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care

W El‐Akel, MH El‐Sayed, M El Kassas… - Journal of viral …, 2017 - Wiley Online Library
Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the
highest prevalence rate worldwide. This necessitated establishing a novel model of care …

[HTML][HTML] Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre …

BM Biccard, PD Gopalan, M Miller, WL Michell… - The Lancet, 2021 - thelancet.com
Background There have been insufficient data for African patients with COVID-19 who are
critically ill. The African COVID-19 Critical Care Outcomes Study (ACCCOS) aimed to …

A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

SS El-Kamary, MD Shardell, M Abdel-Hamid, S Ismail… - Phytomedicine, 2009 - Elsevier
PURPOSE: Milk thistle or its purified extract, silymarin (Silybum marianum), is widely used in
treating acute or chronic hepatitis. Although silymarin is hepatoprotective in animal …

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

D Razavi-Shearer, I Gamkrelidze, C Pan… - The Lancet …, 2023 - thelancet.com
Summary Background The 2016 World Health Assembly endorsed the elimination of
hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and …

Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C‐infected Egyptian cohort: a comparative analysis

M El Kassas, AL Funk, M Salaheldin… - Journal of viral …, 2018 - Wiley Online Library
In Egypt, hepatocellular carcinoma (HCC) is the most common form of cancer and direct‐
acting antivirals (DAA) are administered on a large scale to patients with chronic HCV …

[HTML][HTML] Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations

D Omran, M Alboraie, RA Zayed, MN Wifi… - World journal of …, 2018 - ncbi.nlm.nih.gov
Worldwide, more than one million people die each year from hepatitis C virus (HCV) related
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

V Sapena, M Enea, F Torres, C Celsa, J Rios… - Gut, 2022 - gut.bmj.com
Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

Metabolic syndrome and acute respiratory distress syndrome in hospitalized patients with COVID-19

JL Denson, AS Gillet, Y Zu, M Brown, T Pham… - JAMA network …, 2021 - jamanetwork.com
Importance Obesity, diabetes, and hypertension are common comorbidities in patients with
severe COVID-19, yet little is known about the risk of acute respiratory distress syndrome …